Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Qayed, Muna" or (type any "bookEditor journalEditor issueEditor" and editor="Qayed, Muna")

Add to list
- Journal Article
- A1
- open access
Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial

Theodore W. Laetsch, Shannon L. Maude, Susana Rives, Hidefumi Hiramatsu, Henrique Bittencourt, Peter Bader, André Baruchel, Michael Boyer, Barbara De Moerloose (UGent) , Muna Qayed, et al.

(2022) JOURNAL OF CLINICAL ONCOLOGY. 41(9). p.1664-1669
Add to list
- Journal Article
- A1
- open access
Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia

John E Levine, Stephan A Grupp, Michael A Pulsipher, Andrew C Dietz, Susana Rives, G Douglas Myers, Keith J August, Michael R Verneris, Jochen Buechner, Theodore W Laetsch, et al.

(2021) JOURNAL FOR IMMUNOTHERAPY OF CANCER. 9(8).
Add to list
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

Elena J. Orlando, Xia Han, Catherine Tribouley, Patricia A. Wood, Rebecca J. Leary, Markus Riester, John E. Levine, Muna Qayed, Stephan A. Grupp, Michael Boyer, et al.

(2018) NATURE MEDICINE. 24(10). p.1504-1506
Add to list
Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL)

Stephan A Grupp, Theodore Laetsch, Jochen Buechner, Henrique Bittencourt, Shannon L Maude, Michael R Verneris, Gary D Myers, Michael Boyer, Susana Rives, Barbara De Moerloose (UGent) , et al.

(2016) BLOOD. 128(22).

Academic Bibliography

Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial

Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL)

Contents

Support

Contact